• English
    • Persian
  • English 
    • English
    • Persian
  • Login
View Item 
  •   KR-TBZMED Home
  • TBZMED Published Academics Works
  • Published Articles
  • View Item
  •   KR-TBZMED Home
  • TBZMED Published Academics Works
  • Published Articles
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Effect of IMOD™ on the inflammatory process after acute ischemic stroke: a randomized clinical trial.

Thumbnail
Date
2013
Author
Farhoudi, M
Najafi-Nesheli, M
Hashemilar, M
Mahmoodpoor, A
Sharifipour, E
Baradaran, B
Taheraghdam, A
Savadi-Oskouei, D
Sadeghi-Bazargani, H
Sadeghi-Hokmabadi, E
Akbari, H
Rikhtegar, R
Metadata
Show full item record
Abstract
Considering the role of inflammation in acute cerebrovascular accidents, anti-inflammatory treatment has been considered as an option in cerebrovascular diseases. Regarding the properties of Setarud (IMOD™) in immune regulation, the aim of the present study was to evaluate the role of this medication in treating patients with acute ischemic stroke.In this randomized clinical trial, 99 patients with their first ever acute ischemic stroke were divided into two groups of IMOD™ (n?=?49) and control (n?=?50). The control group underwent routine treatment and the intervention group underwent routine treatment plus daily intermittent infusion of IMOD™ (250mg on the first day and then 375mg into DW5% serum during a 30-minute period for 7 days). The serum levels of inflammatory markers were evaluated on the first day (baseline) and on 4th and 7th days. Data were analyzed and the results were compared.58 males (58.6%) and 41 females (41.4%) with a mean age of 67.00?آ±?8.82 years, who had their first ever stroke attack, were enrolled in this trial. Treatment with IMOD™ showed a decreasing trend in IL-6 levels compared to the control group (p?=?0.04). In addition, the treatment resulted in the control of increasing serum levels of hsCRP after 7 days compared to the control group (p?=?0.02). There was an insignificant decrease in TNF-? and IL-1 levels in the IMOD™ group. Considering the prominent role of inflammation after an ischemic cerebral damage, it appears that treatment with IMOD™ improves the inflammatory profile. Therefore, IMOD™ (Setarud) might be considered as a therapeutic option in the acute ischemic stroke. However, future studies are necessary on its long-term results and clinical efficacy.
URI
http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/42383
Collections
  • Published Articles

Knowledge repository of Tabriz University of Medical Sciences using DSpace software copyright © 2018  HTMLMAP
Contact Us | Send Feedback
Theme by 
Atmire NV
 

 

Browse

All of KR-TBZMEDCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

Knowledge repository of Tabriz University of Medical Sciences using DSpace software copyright © 2018  HTMLMAP
Contact Us | Send Feedback
Theme by 
Atmire NV